Clinical Trial Update: Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial comparing rituximab to glatiramer acetate in secondary progressive multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• GLATIRAMER ACETATE (GLATIRAMER ACETATE)
• Rituximab (rituximab)

Snippet

Sponsor: Isfahan University of Medical Sciences | Conditions: Secondary Progressive Multiple Sclerosis | Phase 2, Phase 3 | Status: COMPLETED